CHRSHIGH SIGNALFINANCIAL10-K

Coherus completed the divestiture of its UDENYCA biosimilar franchise, transforming from a two-product commercial company into a single-product immunotherapy-focused entity with dramatically improved balance sheet metrics.

The UDENYCA sale generated substantial cash proceeds that eliminated the company's negative equity position and reduced total liabilities by 66%, providing financial stability. However, this strategic pivot leaves Coherus highly dependent on LOQTORZI as its sole commercial product, significantly increasing concentration risk while the company develops its early-stage pipeline.

Comparing 2026-03-09 vs 2025-03-17View on EDGAR →
FINANCIAL ANALYSIS

The UDENYCA divestiture created a mixed financial picture with strong balance sheet improvements but operational challenges. While net income surged 489% to $168M (likely from divestiture gains), operating losses deepened 62% to -$181M and operating cash flow deteriorated dramatically from -$20M to -$139M, indicating underlying business struggles. The transformation eliminated inventory (95% decline) and substantially reduced liabilities (66% decrease), converting negative equity of -$132M to positive $61M, but left the company smaller with total assets declining 42% and increased dependence on a single revenue source.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
-577.7%
-$20.4M→-$138.5M

Operating cash flow fell 577.7% — earnings quality concerns; investigate working capital changes and non-cash items.

Net Income
P&L
+489.4%
$28.5M→$168.0M

Net income grew 489.4% — bottom-line growth signals improving overall business health.

Stockholders Equity
Balance Sheet
+146.2%
-$132.0M→$61.0M

Equity base grew 146.2% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Inventory
Balance Sheet
-95.5%
$70.1M→$3.2M

Inventory drawn down 95.5% — strong sell-through or deliberate destocking; watch for supply constraints.

Capital Expenditure
Cash Flow
-86%
$2.0M→$286K

Capex reduced 86% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Interest Expense
P&L
-66.9%
$27.2M→$9.0M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Total Liabilities
Balance Sheet
-66%
$580.5M→$197.3M

Liabilities reduced 66% — deleveraging improves balance sheet strength and financial flexibility.

Operating Income
P&L
-62.2%
-$111.7M→-$181.1M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Current Liabilities
Balance Sheet
-50.4%
$283.0M→$140.4M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Assets
Balance Sheet
-42.4%
$448.5M→$258.3M

Total assets contracted 42.4% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2026-03-09
PRIOR — 2025-03-17
ADDED
Form 10-K Summary 116 Signatures 121 LOQTORZI , whether or not appearing in large print or with the trademark symbol, is a trademark of Coherus.
We have a limited history of profitability, which we have not maintained and may not achieve again, and only one product that has been approved and marketed and with multiple product candidates that are not approved and still in development.
Our product LOQTORZI and product candidates tagmokitug and casdozokitug, if approved, will face significant competition from other immuno-oncology biologics.
If we fail to compete effectively, we may not achieve significant market penetration and expansion .
We are highly dependent on the services of our key executives and personnel, including our President and Chief Executive Officer, Dennis M.
+7 more — sign up free →
REMOVED
Form 10-K Summary 141 Signatures 146 UDENYCA and LOQTORZI , whether or not appearing in large print or with the trademark symbol, are trademarks of Coherus, its affiliates, related companies or its licensors or joint venture partners, unless otherwise noted.
Business Overview We are a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer.
Our commercial portfolio includes our first product, UDENYCA (pegfilgrastim-cbqv), a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor ( G-CSF ) and LOQTORZI (toripalimab-tpzi), a novel next-generation programmed death receptor-1 ( PD-1 ) inhibitor.
We are developing an innovative immuno-oncology pipeline that we expect to bring forward new potential indications for LOQTORZI in the U.S.
UDENYCA was launched commercially in a pre-filled syringe presentation in the United States in January 2019, followed by the launch of UDENYCA in an autoinjector presentation in May 2023 and the launch of UDENYCA ONBODY in February 2024.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →